Natasha A Lannin1,2, Craig S Anderson3,4, Joosup Kim5,6, Monique Kilkenny5,6, Julie Bernhardt6, Christopher Levi7, Helen M Dewey8, Christopher Bladin6,8, Peter Hand9, Helen Castley10, Kelvin Hill11, Steven Faux12, Rohan Grimley13, Brenda Grabsch6, Sandy Middleton10,14, Geoffrey Donnan6, Dominique A Cadilhac5,6. 1. School of Allied Health, La Trobe University, Bundoora, Victoria, Australia. 2. Department of Occupational Therapy, Alfred Health, Prahran, Victoria, Australia. 3. The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia. 4. The George Institute for Global Health China at Peking University Health Science Center, Beijing, China. 5. Stroke and Ageing Research, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia. 6. Florey Institute of Neuroscience and Mental Health, University of Melbourne, Heidelberg, Victoria, Australia. 7. University of Newcastle, Newcastle, New South Wales, Australia. 8. Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia. 9. Royal Melbourne Hospital, Melbourne, Victoria, Australia. 10. Royal Hobart Hospital, Hobart, Tasmania, Australia. 11. National Stroke Foundation, Melbourne, Victoria, Australia. 12. St Vincent's Health Australia, Sydney, New South Wales, Australia. 13. Sunshine Coast Clinical School, The University of Queensland, St Lucia, Queensland, Australia. 14. Australian Catholic University, Sydney, New South Wales, Australia.
Abstract
BACKGROUND: Given the potential differences in etiology and impact, the treatment and outcome of younger patients (aged 18-64 years) require examination separately to older adults (aged ≥65 years) who experience acute stroke. METHODS: Data from the Australian Stroke Clinical Registry (2010-2015) including demographic and clinical characteristics, provision of evidence-based therapies and health-related quality of life (HRQoL) post-stroke was used. Descriptive statistics and multilevel regression models were used for group comparisons. RESULTS: Compared to older patients (age ≥65 years) among 26,220 registrants, 6,526 (25%) younger patients (age 18-64 years) were more often male (63 vs. 51%; p < 0.001), born in Australia (70 vs. 63%; p < 0.001), more often discharged home from acute care (56 vs. 38%; p < 0.001), and less likely to receive antihypertensive medication (61 vs. 73%; p < 0.001). Younger patients had a 74% greater odds of having lower HRQoL compared to an equivalent aged-matched general population (adjusted OR 1.74, 95% CI 1.56-1.93, p < 0.001). CONCLUSIONS: Younger stroke patients exhibited distinct differences from their older counterparts with respect to demographic and clinical characteristics, prescription of antihypertensive medications and residual health status.
BACKGROUND: Given the potential differences in etiology and impact, the treatment and outcome of younger patients (aged 18-64 years) require examination separately to older adults (aged ≥65 years) who experience acute stroke. METHODS: Data from the Australian Stroke Clinical Registry (2010-2015) including demographic and clinical characteristics, provision of evidence-based therapies and health-related quality of life (HRQoL) post-stroke was used. Descriptive statistics and multilevel regression models were used for group comparisons. RESULTS: Compared to older patients (age ≥65 years) among 26,220 registrants, 6,526 (25%) younger patients (age 18-64 years) were more often male (63 vs. 51%; p < 0.001), born in Australia (70 vs. 63%; p < 0.001), more often discharged home from acute care (56 vs. 38%; p < 0.001), and less likely to receive antihypertensive medication (61 vs. 73%; p < 0.001). Younger patients had a 74% greater odds of having lower HRQoL compared to an equivalent aged-matched general population (adjusted OR 1.74, 95% CI 1.56-1.93, p < 0.001). CONCLUSIONS: Younger strokepatients exhibited distinct differences from their older counterparts with respect to demographic and clinical characteristics, prescription of antihypertensive medications and residual health status.
Authors: Raed A Joundi; Joel Adekanye; Alexander A Leung; Paul Ronksley; Eric E Smith; Alexander D Rebchuk; Thalia S Field; Michael D Hill; Stephen B Wilton; Lauren C Bresee Journal: J Am Heart Assoc Date: 2022-06-22 Impact factor: 6.106